Solange Peters, MD, PhD, presented results from the trial evaluating tiragolumab plus atezolizumab.
Non-Small Cell Lung Cancer
Advertisement
John V. Heymach, MD, PhD, of the MD Anderson Cancer Center, presented results from the trial at AACR 2025.
Kathryn C. Arbour, MD, of the Memorial Sloan Kettering Cancer Center, presented results from the study at AACR 2025.
Ivonescimab plus chemotherapy “demonstrated strongly positive results” as a first-line treatment for advanced squamous ...
Dr. Liu discusses key data and updates in EGFR-positive NSCLC from the European Lung Cancer Congress.
Dr. Shaw is being recognized for her "groundbreaking work in defining ALK- and ROS1-positive lung cancers," officials said.
A recent study may provide a "clearer, more individualized" understanding of progression risk after discontinuation.
Margarita Majem, MD, PhD, presented the results as a late-breaking abstract during the European Lung Cancer Congress 2025.
PALOMA-2 used data from PALOMA-3 to evaluate subcutaneous versus intravenous amivantamab for EGFR-mutated NSCLC.
The session covered everything from new actionable immune checkpoints to vaccines, cellular therapies, and bispecifics.
Martin Reck, MD, PhD, reflects on key updates in stage III NSCLC from the European Lung Cancer Congress 2025.
Stephen V. Liu, MD, weighs in on the data from the preplanned interim analysis that was recently published in The Lancet.
Martin Reck, MD, PhD, presented the final analysis at the European Lung Cancer Congress 2025.
Subcutaneous pembrolizumab may be “a viable treatment option" in indications where pembrolizumab is approved.
Andrea Riccardo Filippi, MD, presented survival data from the final PACIFIC-R data extraction with over 5 years of follow-up.
Expert Interviews
Advertisement
Section Editor
Stephen V. Liu, MDThoracic Medical Oncologist | Georgetown University
Advertisement
Latest News
April 28, 2025
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.